A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This study will compare the efficacy and safety of unesbulin plus dacarbazine versus placebo
plus dacarbazine in participants with unresectable or metastatic, relapsed or refractory LMS
who have received at least 1 prior line of systemic therapy.